Tumor Biology

, Volume 35, Issue 5, pp 4177–4183 | Cite as

RETRACTED ARTICLE: MicroRNA-320 inhibits osteosarcoma cells proliferation by directly targeting fatty acid synthase

Research Article


Increasing evidence has demonstrated that small noncoding microRNAs (miRNAs) could contribute to cancer development and progression. Besides, they are differentially expressed in human tumor tissues. In the current study, we found that miR-320 was significantly downregulated in human osteosarcoma tissues, compared with adjacent normal tissues. Introduction of miR-320 mimics into U2OS and MG63 cells inhibited cell proliferation, while cell apoptosis rate remained unaltered. Additionally, miR-320 overexpression could also suppress tumor growth in the nude mice. At the molecular level, our results further revealed that the expression of fatty acid synthase (FASN), a key enzyme for de novo biosynthesis of fatty acids, was negatively regulated by miR-320. Therefore, our results suggest that miR-320 may act as a tumor suppressor for osteosarcoma.


Osteosarcoma MicroRNA miR-320 FASN 


Conflicts of interest



  1. 1.
    Ando K, Heymann MF, Stresing V, et al. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 2013;5:591–616.CrossRefGoogle Scholar
  2. 2.
    Sun K, Lai EC. Adult-specific functions of animal microRNAs. Nat Rev Genet. 2013;14:535–48.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74.CrossRefPubMedGoogle Scholar
  4. 4.
    Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11:849–64.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chou J, Shahi P, Werb Z. microRNA-mediated regulation of the tumor microenvironment. Cell Cycle. 2013;12:3262–71.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sandoval J, Peiró-Chova L, Pallardó FV, García-Giménez JL. Epigenetic biomarkers in laboratory diagnostics: emerging approaches and opportunities. Expert Rev Mol Diagn. 2013;13:457–71.CrossRefPubMedGoogle Scholar
  7. 7.
    Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013;15:546–54.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Li J, Lu X. The emerging roles of 3′ untranslated regions in cancer. Cancer Lett. 2013;337:22–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Hsieh IS, Chang KC, Tsai YT, Ke JY, et al. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis. 2013;34:530–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Schaar DG, Medina DJ, Moore DF, Strair RK, Ting Y. miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation. Exp Hematol. 2009;37:245–55.CrossRefPubMedGoogle Scholar
  11. 11.
    Bronisz A, Godlewski J, Wallace JA, et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol. 2011;14:159–67.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wu YY, Chen YL, Jao YC, et al. miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. Angiogenesis. 2013 Oct 10.Google Scholar
  13. 13.
    Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763–77.CrossRefPubMedGoogle Scholar
  14. 14.
    Zaytseva YY, Rychahou PG, Gulhati P, et al. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res. 2012;72:1504–17.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zhou W, Simpson PJ, McFadden JM, et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res. 2003;63:7330–7.PubMedGoogle Scholar
  16. 16.
    Menendez JA, Vellon L, Mehmi I, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A. 2004;101:10715–20.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Liu ZL, Wang G, Peng AF, et al. Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis. Oncol Lett. 2012;4:878–82.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Liu ZL, Zhou Y, Luo QF, et al. Inhibition of fatty acid synthase suppresses osteosarcoma cell invasion and migration. Indian J Pathol Microbiol. 2012;55:163–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010;6:551–62.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol. 2011;223:283–94.CrossRefPubMedGoogle Scholar
  21. 21.
    Mao JH, Zhou RP, Peng AF, et al. microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN. Oncol Lett. 2012;4:1125–9.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Long XH, Mao JH, Peng AF, et al. Tumor suppressive microRNA-424 inhibits osteosarcoma cell migration and invasion via targeting fatty acid synthase. Exp Ther Med. 2013;5:1048–52.PubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of OsteologyFeicheng People’s HospitalTai’anChina
  2. 2.Department of OsteologyLiaocheng People’s Hospital, LiaochengLiaochengChina
  3. 3.Surgical Ward No. 7Shandong Cancer HospitalJinanChina

Personalised recommendations